VYGR
Voyager Therapeutics, Inc. · Healthcare
Insiders sold $184K of Voyager Therapeutics, Inc. in the last 12 months and bought none
VYGR over the last year
VYGR after insider buys
3 months after each buy, from the first price a copier could get.
4 buys since 2016 with 3 months of prices.
Every filing
57 insider filings since 2016, newest first
Alfred Sandrock · President and CEO
Alfred Sandrock · President and CEO
Alfred Sandrock · President and CEO
Alfred Sandrock · President and CEO
Sandell Jacquelyn Fahey · General Counsel
Alfred Sandrock · President and CEO
Alfred Sandrock · President and CEO
Robin Swartz · COO
Peter P. Pfreundschuh · CFO
Todd Alfred Carter · Chief Scientific Officer
Peter P. Pfreundschuh · CFO
Todd Alfred Carter · Chief Scientific Officer
Todd Alfred Carter · Chief Scientific Officer
Todd Alfred Carter · Chief Scientific Officer
Alfred Sandrock · President and CEO
Robin Swartz · COO
Robert W. Hesslein · SVP and General Counsel
Robin Swartz · COO
Neurocrine Biosciences Inc · 10% owner
Third Rock Ventures Iii, L.P. · 10% owner
Third Rock Ventures Iii, L.P. · 10% owner
Third Rock Ventures Iii, L.P. · 10% owner
Third Rock Ventures Iii, L.P. · 10% owner
Ecor1 Capital, LLC · 10% owner
Third Rock Ventures Iii, L.P. · 10% owner
Third Rock Ventures Iii, L.P. · 10% owner
Third Rock Ventures Iii, L.P. · 10% owner
Glenn Pierce · Director
Michael J Higgins · Director
Robin Swartz · COO
Robert W. Hesslein · SVP and General Counsel
Andre Turenne · President and CEO
Omar Khwaja · Insider
Andre Turenne · President and CEO
Allison Dorval · CFO
Omar Khwaja · Insider
Robert W. Hesslein · SVP and General Counsel
Allison Dorval · CFO
Matthew P. Ottmer · COO
Andre Turenne · President and CEO
Neurocrine Biosciences Inc · 10% owner
James A Geraghty · Director
Glenn Pierce · Director
James A Geraghty · Director
Bernard Ravina · Chief Medical Officer
Jane Henderson · SVP, CFO, Corp. Dev.
Jane Henderson · CFO, SVP, Corp. Dev.
Bernard Ravina · Chief Medical Officer
Dinah Ph.d. Sah · Chief Scientific Officer
Bernard Ravina · Chief Medical Officer
About Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.